ParkinsonFranceV1, PascalFrancis, Corpus, bibRecord, 001632

Early treatment of Parkinson's Disease with cabergoline delays the onset of motor complications: Results of a double-blind levodopa controlled trial

Identifieur interne : 001632 ( PascalFrancis/Corpus ); précédent : 001631; suivant : 001633

Early treatment of Parkinson's Disease with cabergoline delays the onset of motor complications: Results of a double-blind levodopa controlled trial

Auteurs : U. K. Rinne ; F. Bracco ; C. Chouza ; E. Dupont ; O. Gershanik ; J. F. Marti Masso ; J. L. Montastruc ; C. D. Marsden

Source :

Drugs : (Basel) [ 0012-6667 ] ; 1998.

RBID : Pascal:98-0176336

Descripteurs français

Pascal (Inist)
- Cabergoline, Chimiothérapie, Traitement, Précoce, Prévention, Toxicité, Parkinson maladie, Homme, Etude multicentrique, Randomisation, Etude double insu, Essai thérapeutique contrôlé, Ergot dérivé.

English descriptors

KwdEn :
- Cabergoline, Chemotherapy, Controlled therapeutic trial, Double blind study, Early, Ergot derivatives, Human, Multicenter study, Parkinson disease, Prevention, Randomization, Toxicity, Treatment.

Abstract

This multicentre randomised double-blind 3- to 5-year trial was designed to assess whether initial therapy with cabergoline alone or in combination with levodopa prevents or delays the occurrence of long term motor complications in patients with early Parkinson's disease. Patients eligible for study inclusion (n = 412) had early idiopathic Parkinson's disease (Hoehn and Yahr stages 1 to 3) and had received no previous treatment with levodopa, selegiline or dopamine agonists. Patients were randomised to receive either cabergoline (0.25 to 4mg once daily) or levodopa (100 to 600 mg/day) titrated over a maximum period of 24 weeks. Once the optimum or maximum tolerated dose was achieved, it was maintained up to the end-point (development of motor complications confirmed at 2 consecutive 3-month visits) or up to a minimum of 3 years' treatment. Open labelled levodopa was added in both treatment arms when the improvement in motor disability [Unified Parkinson's Disease Rating Scale (UPDRS) factor III] decreased below 30% vs baseline. Both treatments improved motor disability, decreasing UPDRS factor III scores and factor II scores for activities of daily living. The development of motor complications (end-point) was significantly less frequent in patients treated with cabergoline than in levodopa recipients (22% vs 34% ; p < 0.02). The relative risk of developing motor complications during treatment with cabergoline was more than 50% lower than with levodopa. Serious adverse events, either drug related or not, were slightly more frequent in cabergoline-treated patients (31%) than in those treated with levodopa (25%). The withdrawal rate in the cabergoline v-I levodopa group was 16 vs 13%. In conclusion, the study shows that, in patients with early Parkinson's disease, cabergoline is effective either as monotherapy or combined with levodopa. Moreover, starting treatment with cabergoline significantly delays the development of motor complications.

Notice en format standard (ISO 2709)

Pour connaître la documentation sur le format Inist Standard.

A01	`01`	`1`		`@0 0012-6667`
A02	`01`			`@0 DRUGAY`
A03		`1`		`@0 Drugs : (Basel)`
A05				`@2 55`
A06				`@3 SUP1`
A08	`01`	`1`	`ENG`	`@1 Early treatment of Parkinson's Disease with cabergoline delays the onset of motor complications: Results of a double-blind levodopa controlled trial`
A09	`01`	`1`	`ENG`	`@1 Cabergoline: advantages of sustained dopaminergic stimulation`
A11	`01`	`1`		`@1 RINNE (U. K.)`
A11	`02`	`1`		`@1 BRACCO (F.)`
A11	`03`	`1`		`@1 CHOUZA (C.)`
A11	`04`	`1`		`@1 DUPONT (E.)`
A11	`05`	`1`		`@1 GERSHANIK (O.)`
A11	`06`	`1`		`@1 MARTI MASSO (J. F.)`
A11	`07`	`1`		`@1 MONTASTRUC (J. L.)`
A11	`08`	`1`		`@1 MARSDEN (C. D.)`
A12	`01`	`1`		`@1 MARSDEN (C. D.) @9 ed.`
A14	`01`			`@1 Department of Neurology, University of Turku @2 Turku @3 FIN @Z 1 aut.`
A14	`02`			`@1 Clinica Neurologica, Università di Padova @2 Padova @3 ITA @Z 2 aut.`
A14	`03`			`@1 Instituto de Neurologia, Hospital de Clinicas @2 Montevideo @3 URY @Z 3 aut.`
A14	`04`			`@1 Department of Neurology, Århus Kommunehospital @2 Århus @3 DNK @Z 4 aut.`
A14	`05`			`@1 Centro Neurologico, Hospital Frances @2 Buenos Aires @3 ARG @Z 5 aut.`
A14	`06`			`@1 Department of Neurology, Hospital Ntra. Sra. de Aranzazu @2 San Sebastian @3 ESP @Z 6 aut.`
A14	`07`			`@1 Centre Hospitalier Universitaire @2 Toulouse @3 FRA @Z 7 aut.`
A14	`08`			`@1 The National Hospital for Neurology and Neurosurgery @2 London @3 GBR @Z 8 aut.`
A15	`01`			`@1 Institute of Neurology, and The National Hospital for Neurology and Neurosurgery @2 London @3 GBR @Z 1 aut.`
A17	`01`	`1`		`@1 PKDS009 Study Group @3 INC`
A20				`@1 23-30`
A21				`@1 1998`
A23	`01`			`@0 ENG`
A43	`01`			`@1 INIST @2 15326 @5 354000078173570040`
A44				`@0 0000 @1 © 1998 INIST-CNRS. All rights reserved.`
A45				`@0 21 ref.`
A47	`01`	`1`		`@0 98-0176336`
A60				`@1 P @2 C`
A61				`@0 A`
A64		`1`		`@0 Drugs : (Basel)`
A66	`01`			`@0 NZL`
C01	`01`		`ENG`	@0 This multicentre randomised double-blind 3- to 5-year trial was designed to assess whether initial therapy with cabergoline alone or in combination with levodopa prevents or delays the occurrence of long term motor complications in patients with early Parkinson's disease. Patients eligible for study inclusion (n = 412) had early idiopathic Parkinson's disease (Hoehn and Yahr stages 1 to 3) and had received no previous treatment with levodopa, selegiline or dopamine agonists. Patients were randomised to receive either cabergoline (0.25 to 4mg once daily) or levodopa (100 to 600 mg/day) titrated over a maximum period of 24 weeks. Once the optimum or maximum tolerated dose was achieved, it was maintained up to the end-point (development of motor complications confirmed at 2 consecutive 3-month visits) or up to a minimum of 3 years' treatment. Open labelled levodopa was added in both treatment arms when the improvement in motor disability [Unified Parkinson's Disease Rating Scale (UPDRS) factor III] decreased below 30% vs baseline. Both treatments improved motor disability, decreasing UPDRS factor III scores and factor II scores for activities of daily living. The development of motor complications (end-point) was significantly less frequent in patients treated with cabergoline than in levodopa recipients (22% vs 34% ; p < 0.02). The relative risk of developing motor complications during treatment with cabergoline was more than 50% lower than with levodopa. Serious adverse events, either drug related or not, were slightly more frequent in cabergoline-treated patients (31%) than in those treated with levodopa (25%). The withdrawal rate in the cabergoline v-I levodopa group was 16 vs 13%. In conclusion, the study shows that, in patients with early Parkinson's disease, cabergoline is effective either as monotherapy or combined with levodopa. Moreover, starting treatment with cabergoline significantly delays the development of motor complications.
C02	`01`	`X`		`@0 002B02B06`
C03	`01`	`X`	`FRE`	`@0 Cabergoline @2 NK @2 FR @5 01`
C03	`01`	`X`	`ENG`	`@0 Cabergoline @2 NK @2 FR @5 01`
C03	`01`	`X`	`SPA`	`@0 Cabergolina @2 NK @2 FR @5 01`
C03	`02`	`X`	`FRE`	`@0 Chimiothérapie @5 04`
C03	`02`	`X`	`ENG`	`@0 Chemotherapy @5 04`
C03	`02`	`X`	`SPA`	`@0 Quimioterapia @5 04`
C03	`03`	`X`	`FRE`	`@0 Traitement @5 07`
C03	`03`	`X`	`ENG`	`@0 Treatment @5 07`
C03	`03`	`X`	`GER`	`@0 Aufbereiten @5 07`
C03	`03`	`X`	`SPA`	`@0 Tratamiento @5 07`
C03	`04`	`X`	`FRE`	`@0 Précoce @5 10`
C03	`04`	`X`	`ENG`	`@0 Early @5 10`
C03	`04`	`X`	`SPA`	`@0 Precoz @5 10`
C03	`05`	`X`	`FRE`	`@0 Prévention @5 11`
C03	`05`	`X`	`ENG`	`@0 Prevention @5 11`
C03	`05`	`X`	`SPA`	`@0 Prevención @5 11`
C03	`06`	`X`	`FRE`	`@0 Toxicité @5 12`
C03	`06`	`X`	`ENG`	`@0 Toxicity @5 12`
C03	`06`	`X`	`GER`	`@0 Giftigkeit @5 12`
C03	`06`	`X`	`SPA`	`@0 Toxicidad @5 12`
C03	`07`	`X`	`FRE`	`@0 Parkinson maladie @5 13`
C03	`07`	`X`	`ENG`	`@0 Parkinson disease @5 13`
C03	`07`	`X`	`SPA`	`@0 Parkinson enfermedad @5 13`
C03	`08`	`X`	`FRE`	`@0 Homme @5 14`
C03	`08`	`X`	`ENG`	`@0 Human @5 14`
C03	`08`	`X`	`SPA`	`@0 Hombre @5 14`
C03	`09`	`X`	`FRE`	`@0 Etude multicentrique @5 16`
C03	`09`	`X`	`ENG`	`@0 Multicenter study @5 16`
C03	`09`	`X`	`SPA`	`@0 Estudio multicéntrico @5 16`
C03	`10`	`X`	`FRE`	`@0 Randomisation @5 17`
C03	`10`	`X`	`ENG`	`@0 Randomization @5 17`
C03	`10`	`X`	`SPA`	`@0 Aleatorización @5 17`
C03	`11`	`X`	`FRE`	`@0 Etude double insu @5 18`
C03	`11`	`X`	`ENG`	`@0 Double blind study @5 18`
C03	`11`	`X`	`SPA`	`@0 Estudio doble ciego @5 18`
C03	`12`	`X`	`FRE`	`@0 Essai thérapeutique contrôlé @5 19`
C03	`12`	`X`	`ENG`	`@0 Controlled therapeutic trial @5 19`
C03	`12`	`X`	`SPA`	`@0 Ensayo terapéutico controlado @5 19`
C03	`13`	`X`	`FRE`	`@0 Ergot dérivé @5 25`
C03	`13`	`X`	`ENG`	`@0 Ergot derivatives @5 25`
C03	`13`	`X`	`SPA`	`@0 Ergot derivado @5 25`
C07	`01`	`X`	`FRE`	`@0 Système nerveux pathologie @5 69`
C07	`01`	`X`	`ENG`	`@0 Nervous system diseases @5 69`
C07	`01`	`X`	`SPA`	`@0 Sistema nervioso patología @5 69`
C07	`02`	`X`	`FRE`	`@0 Système nerveux central pathologie @5 70`
C07	`02`	`X`	`ENG`	`@0 Central nervous system disease @5 70`
C07	`02`	`X`	`SPA`	`@0 Sistema nervosio central patología @5 70`
C07	`03`	`X`	`FRE`	`@0 Encéphale pathologie @5 71`
C07	`03`	`X`	`ENG`	`@0 Cerebral disorder @5 71`
C07	`03`	`X`	`SPA`	`@0 Encéfalo patología @5 71`
C07	`04`	`X`	`FRE`	`@0 Extrapyramidal syndrome @5 72`
C07	`04`	`X`	`ENG`	`@0 Extrapyramidal syndrome @5 72`
C07	`04`	`X`	`SPA`	`@0 Extrapiramidal síndrome @5 72`
C07	`05`	`X`	`FRE`	`@0 Maladie dégénérative @5 73`
C07	`05`	`X`	`ENG`	`@0 Degenerative disease @5 73`
C07	`05`	`X`	`SPA`	`@0 Enfermedad degenerativa @5 73`
N21				`@1 117`

A30	`01`	`1`	`ENG`	`@1 Cabergoline: Advantages of Sustained Dopaminergic Stimulation. Satellite Symposium @3 London GBR @4 1997-03`

Format Inist (serveur)

NO :	PASCAL 98-0176336 INIST
ET :	Early treatment of Parkinson's Disease with cabergoline delays the onset of motor complications: Results of a double-blind levodopa controlled trial
AU :	RINNE (U. K.); BRACCO (F.); CHOUZA (C.); DUPONT (E.); GERSHANIK (O.); MARTI MASSO (J. F.); MONTASTRUC (J. L.); MARSDEN (C. D.); MARSDEN (C. D.)
AF :	Department of Neurology, University of Turku/Turku/Finlande (1 aut.); Clinica Neurologica, Università di Padova/Padova/Italie (2 aut.); Instituto de Neurologia, Hospital de Clinicas/Montevideo/Uruguay (3 aut.); Department of Neurology, Århus Kommunehospital/Århus/Danemark (4 aut.); Centro Neurologico, Hospital Frances/Buenos Aires/Argentine (5 aut.); Department of Neurology, Hospital Ntra. Sra. de Aranzazu/San Sebastian/Espagne (6 aut.); Centre Hospitalier Universitaire/Toulouse/France (7 aut.); The National Hospital for Neurology and Neurosurgery/London/Royaume-Uni (8 aut.); Institute of Neurology, and The National Hospital for Neurology and Neurosurgery/London/Royaume-Uni (1 aut.)
DT :	Publication en série; Congrès; Niveau analytique
SO :	Drugs : (Basel); ISSN 0012-6667; Coden DRUGAY; Nouvelle-Zélande; Da. 1998; Vol. 55; No. SUP1; Pp. 23-30; Bibl. 21 ref.
LA :	Anglais
EA :	This multicentre randomised double-blind 3- to 5-year trial was designed to assess whether initial therapy with cabergoline alone or in combination with levodopa prevents or delays the occurrence of long term motor complications in patients with early Parkinson's disease. Patients eligible for study inclusion (n = 412) had early idiopathic Parkinson's disease (Hoehn and Yahr stages 1 to 3) and had received no previous treatment with levodopa, selegiline or dopamine agonists. Patients were randomised to receive either cabergoline (0.25 to 4mg once daily) or levodopa (100 to 600 mg/day) titrated over a maximum period of 24 weeks. Once the optimum or maximum tolerated dose was achieved, it was maintained up to the end-point (development of motor complications confirmed at 2 consecutive 3-month visits) or up to a minimum of 3 years' treatment. Open labelled levodopa was added in both treatment arms when the improvement in motor disability [Unified Parkinson's Disease Rating Scale (UPDRS) factor III] decreased below 30% vs baseline. Both treatments improved motor disability, decreasing UPDRS factor III scores and factor II scores for activities of daily living. The development of motor complications (end-point) was significantly less frequent in patients treated with cabergoline than in levodopa recipients (22% vs 34% ; p < 0.02). The relative risk of developing motor complications during treatment with cabergoline was more than 50% lower than with levodopa. Serious adverse events, either drug related or not, were slightly more frequent in cabergoline-treated patients (31%) than in those treated with levodopa (25%). The withdrawal rate in the cabergoline v-I levodopa group was 16 vs 13%. In conclusion, the study shows that, in patients with early Parkinson's disease, cabergoline is effective either as monotherapy or combined with levodopa. Moreover, starting treatment with cabergoline significantly delays the development of motor complications.
CC :	002B02B06
FD :	Cabergoline; Chimiothérapie; Traitement; Précoce; Prévention; Toxicité; Parkinson maladie; Homme; Etude multicentrique; Randomisation; Etude double insu; Essai thérapeutique contrôlé; Ergot dérivé
FG :	Système nerveux pathologie; Système nerveux central pathologie; Encéphale pathologie; Extrapyramidal syndrome; Maladie dégénérative
ED :	Cabergoline; Chemotherapy; Treatment; Early; Prevention; Toxicity; Parkinson disease; Human; Multicenter study; Randomization; Double blind study; Controlled therapeutic trial; Ergot derivatives
EG :	Nervous system diseases; Central nervous system disease; Cerebral disorder; Extrapyramidal syndrome; Degenerative disease
GD :	Aufbereiten; Giftigkeit
SD :	Cabergolina; Quimioterapia; Tratamiento; Precoz; Prevención; Toxicidad; Parkinson enfermedad; Hombre; Estudio multicéntrico; Aleatorización; Estudio doble ciego; Ensayo terapéutico controlado; Ergot derivado
LO :	INIST-15326.354000078173570040
ID :	98-0176336

Links to Exploration step

Pascal:98-0176336

Le document en format XML

<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en" level="a">Early treatment of Parkinson's Disease with cabergoline delays the onset of motor complications: Results of a double-blind levodopa controlled trial</title>
<author><name sortKey="Rinne, U K" sort="Rinne, U K" uniqKey="Rinne U" first="U. K." last="Rinne">U. K. Rinne</name>
<affiliation><inist:fA14 i1="01"><s1>Department of Neurology, University of Turku</s1>
<s2>Turku</s2>
<s3>FIN</s3>
<sZ>1 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author><name sortKey="Bracco, F" sort="Bracco, F" uniqKey="Bracco F" first="F." last="Bracco">F. Bracco</name>
<affiliation><inist:fA14 i1="02"><s1>Clinica Neurologica, Università di Padova</s1>
<s2>Padova</s2>
<s3>ITA</s3>
<sZ>2 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author><name sortKey="Chouza, C" sort="Chouza, C" uniqKey="Chouza C" first="C." last="Chouza">C. Chouza</name>
<affiliation><inist:fA14 i1="03"><s1>Instituto de Neurologia, Hospital de Clinicas</s1>
<s2>Montevideo</s2>
<s3>URY</s3>
<sZ>3 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author><name sortKey="Dupont, E" sort="Dupont, E" uniqKey="Dupont E" first="E." last="Dupont">E. Dupont</name>
<affiliation><inist:fA14 i1="04"><s1>Department of Neurology, Århus Kommunehospital</s1>
<s2>Århus</s2>
<s3>DNK</s3>
<sZ>4 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author><name sortKey="Gershanik, O" sort="Gershanik, O" uniqKey="Gershanik O" first="O." last="Gershanik">O. Gershanik</name>
<affiliation><inist:fA14 i1="05"><s1>Centro Neurologico, Hospital Frances</s1>
<s2>Buenos Aires</s2>
<s3>ARG</s3>
<sZ>5 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author><name sortKey="Marti Masso, J F" sort="Marti Masso, J F" uniqKey="Marti Masso J" first="J. F." last="Marti Masso">J. F. Marti Masso</name>
<affiliation><inist:fA14 i1="06"><s1>Department of Neurology, Hospital Ntra. Sra. de Aranzazu</s1>
<s2>San Sebastian</s2>
<s3>ESP</s3>
<sZ>6 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author><name sortKey="Montastruc, J L" sort="Montastruc, J L" uniqKey="Montastruc J" first="J. L." last="Montastruc">J. L. Montastruc</name>
<affiliation><inist:fA14 i1="07"><s1>Centre Hospitalier Universitaire</s1>
<s2>Toulouse</s2>
<s3>FRA</s3>
<sZ>7 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author><name sortKey="Marsden, C D" sort="Marsden, C D" uniqKey="Marsden C" first="C. D." last="Marsden">C. D. Marsden</name>
<affiliation><inist:fA14 i1="08"><s1>The National Hospital for Neurology and Neurosurgery</s1>
<s2>London</s2>
<s3>GBR</s3>
<sZ>8 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
</titleStmt>
<publicationStmt><idno type="wicri:source">INIST</idno>
<idno type="inist">98-0176336</idno>
<date when="1998">1998</date>
<idno type="stanalyst">PASCAL 98-0176336 INIST</idno>
<idno type="RBID">Pascal:98-0176336</idno>
<idno type="wicri:Area/PascalFrancis/Corpus">001632</idno>
</publicationStmt>
<sourceDesc><biblStruct><analytic><title xml:lang="en" level="a">Early treatment of Parkinson's Disease with cabergoline delays the onset of motor complications: Results of a double-blind levodopa controlled trial</title>
<author><name sortKey="Rinne, U K" sort="Rinne, U K" uniqKey="Rinne U" first="U. K." last="Rinne">U. K. Rinne</name>
<affiliation><inist:fA14 i1="01"><s1>Department of Neurology, University of Turku</s1>
<s2>Turku</s2>
<s3>FIN</s3>
<sZ>1 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author><name sortKey="Bracco, F" sort="Bracco, F" uniqKey="Bracco F" first="F." last="Bracco">F. Bracco</name>
<affiliation><inist:fA14 i1="02"><s1>Clinica Neurologica, Università di Padova</s1>
<s2>Padova</s2>
<s3>ITA</s3>
<sZ>2 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author><name sortKey="Chouza, C" sort="Chouza, C" uniqKey="Chouza C" first="C." last="Chouza">C. Chouza</name>
<affiliation><inist:fA14 i1="03"><s1>Instituto de Neurologia, Hospital de Clinicas</s1>
<s2>Montevideo</s2>
<s3>URY</s3>
<sZ>3 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author><name sortKey="Dupont, E" sort="Dupont, E" uniqKey="Dupont E" first="E." last="Dupont">E. Dupont</name>
<affiliation><inist:fA14 i1="04"><s1>Department of Neurology, Århus Kommunehospital</s1>
<s2>Århus</s2>
<s3>DNK</s3>
<sZ>4 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author><name sortKey="Gershanik, O" sort="Gershanik, O" uniqKey="Gershanik O" first="O." last="Gershanik">O. Gershanik</name>
<affiliation><inist:fA14 i1="05"><s1>Centro Neurologico, Hospital Frances</s1>
<s2>Buenos Aires</s2>
<s3>ARG</s3>
<sZ>5 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author><name sortKey="Marti Masso, J F" sort="Marti Masso, J F" uniqKey="Marti Masso J" first="J. F." last="Marti Masso">J. F. Marti Masso</name>
<affiliation><inist:fA14 i1="06"><s1>Department of Neurology, Hospital Ntra. Sra. de Aranzazu</s1>
<s2>San Sebastian</s2>
<s3>ESP</s3>
<sZ>6 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author><name sortKey="Montastruc, J L" sort="Montastruc, J L" uniqKey="Montastruc J" first="J. L." last="Montastruc">J. L. Montastruc</name>
<affiliation><inist:fA14 i1="07"><s1>Centre Hospitalier Universitaire</s1>
<s2>Toulouse</s2>
<s3>FRA</s3>
<sZ>7 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author><name sortKey="Marsden, C D" sort="Marsden, C D" uniqKey="Marsden C" first="C. D." last="Marsden">C. D. Marsden</name>
<affiliation><inist:fA14 i1="08"><s1>The National Hospital for Neurology and Neurosurgery</s1>
<s2>London</s2>
<s3>GBR</s3>
<sZ>8 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
</analytic>
<series><title level="j" type="main">Drugs : (Basel)</title>
<title level="j" type="abbreviated">Drugs : (Basel)</title>
<idno type="ISSN">0012-6667</idno>
<imprint><date when="1998">1998</date>
</imprint>
</series>
</biblStruct>
</sourceDesc>
<seriesStmt><title level="j" type="main">Drugs : (Basel)</title>
<title level="j" type="abbreviated">Drugs : (Basel)</title>
<idno type="ISSN">0012-6667</idno>
</seriesStmt>
</fileDesc>
<profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Cabergoline</term>
<term>Chemotherapy</term>
<term>Controlled therapeutic trial</term>
<term>Double blind study</term>
<term>Early</term>
<term>Ergot derivatives</term>
<term>Human</term>
<term>Multicenter study</term>
<term>Parkinson disease</term>
<term>Prevention</term>
<term>Randomization</term>
<term>Toxicity</term>
<term>Treatment</term>
</keywords>
<keywords scheme="Pascal" xml:lang="fr"><term>Cabergoline</term>
<term>Chimiothérapie</term>
<term>Traitement</term>
<term>Précoce</term>
<term>Prévention</term>
<term>Toxicité</term>
<term>Parkinson maladie</term>
<term>Homme</term>
<term>Etude multicentrique</term>
<term>Randomisation</term>
<term>Etude double insu</term>
<term>Essai thérapeutique contrôlé</term>
<term>Ergot dérivé</term>
</keywords>
</textClass>
</profileDesc>
</teiHeader>
<front><div type="abstract" xml:lang="en">This multicentre randomised double-blind 3- to 5-year trial was designed to assess whether initial therapy with cabergoline alone or in combination with levodopa prevents or delays the occurrence of long term motor complications in patients with early Parkinson's disease. Patients eligible for study inclusion (n = 412) had early idiopathic Parkinson's disease (Hoehn and Yahr stages 1 to 3) and had received no previous treatment with levodopa, selegiline or dopamine agonists. Patients were randomised to receive either cabergoline (0.25 to 4mg once daily) or levodopa (100 to 600 mg/day) titrated over a maximum period of 24 weeks. Once the optimum or maximum tolerated dose was achieved, it was maintained up to the end-point (development of motor complications confirmed at 2 consecutive 3-month visits) or up to a minimum of 3 years' treatment. Open labelled levodopa was added in both treatment arms when the improvement in motor disability [Unified Parkinson's Disease Rating Scale (UPDRS) factor III] decreased below 30% vs baseline. Both treatments improved motor disability, decreasing UPDRS factor III scores and factor II scores for activities of daily living. The development of motor complications (end-point) was significantly less frequent in patients treated with cabergoline than in levodopa recipients (22% vs 34% ; p < 0.02). The relative risk of developing motor complications during treatment with cabergoline was more than 50% lower than with levodopa. Serious adverse events, either drug related or not, were slightly more frequent in cabergoline-treated patients (31%) than in those treated with levodopa (25%). The withdrawal rate in the cabergoline v-I levodopa group was 16 vs 13%. In conclusion, the study shows that, in patients with early Parkinson's disease, cabergoline is effective either as monotherapy or combined with levodopa. Moreover, starting treatment with cabergoline significantly delays the development of motor complications.</div>
</front>
</TEI>
<inist><standard h6="B"><pA><fA01 i1="01" i2="1"><s0>0012-6667</s0>
</fA01>
<fA02 i1="01"><s0>DRUGAY</s0>
</fA02>
<fA03 i2="1"><s0>Drugs : (Basel)</s0>
</fA03>
<fA05><s2>55</s2>
</fA05>
<fA06><s3>SUP1</s3>
</fA06>
<fA08 i1="01" i2="1" l="ENG"><s1>Early treatment of Parkinson's Disease with cabergoline delays the onset of motor complications: Results of a double-blind levodopa controlled trial</s1>
</fA08>
<fA09 i1="01" i2="1" l="ENG"><s1>Cabergoline: advantages of sustained dopaminergic stimulation</s1>
</fA09>
<fA11 i1="01" i2="1"><s1>RINNE (U. K.)</s1>
</fA11>
<fA11 i1="02" i2="1"><s1>BRACCO (F.)</s1>
</fA11>
<fA11 i1="03" i2="1"><s1>CHOUZA (C.)</s1>
</fA11>
<fA11 i1="04" i2="1"><s1>DUPONT (E.)</s1>
</fA11>
<fA11 i1="05" i2="1"><s1>GERSHANIK (O.)</s1>
</fA11>
<fA11 i1="06" i2="1"><s1>MARTI MASSO (J. F.)</s1>
</fA11>
<fA11 i1="07" i2="1"><s1>MONTASTRUC (J. L.)</s1>
</fA11>
<fA11 i1="08" i2="1"><s1>MARSDEN (C. D.)</s1>
</fA11>
<fA12 i1="01" i2="1"><s1>MARSDEN (C. D.)</s1>
<s9>ed.</s9>
</fA12>
<fA14 i1="01"><s1>Department of Neurology, University of Turku</s1>
<s2>Turku</s2>
<s3>FIN</s3>
<sZ>1 aut.</sZ>
</fA14>
<fA14 i1="02"><s1>Clinica Neurologica, Università di Padova</s1>
<s2>Padova</s2>
<s3>ITA</s3>
<sZ>2 aut.</sZ>
</fA14>
<fA14 i1="03"><s1>Instituto de Neurologia, Hospital de Clinicas</s1>
<s2>Montevideo</s2>
<s3>URY</s3>
<sZ>3 aut.</sZ>
</fA14>
<fA14 i1="04"><s1>Department of Neurology, Århus Kommunehospital</s1>
<s2>Århus</s2>
<s3>DNK</s3>
<sZ>4 aut.</sZ>
</fA14>
<fA14 i1="05"><s1>Centro Neurologico, Hospital Frances</s1>
<s2>Buenos Aires</s2>
<s3>ARG</s3>
<sZ>5 aut.</sZ>
</fA14>
<fA14 i1="06"><s1>Department of Neurology, Hospital Ntra. Sra. de Aranzazu</s1>
<s2>San Sebastian</s2>
<s3>ESP</s3>
<sZ>6 aut.</sZ>
</fA14>
<fA14 i1="07"><s1>Centre Hospitalier Universitaire</s1>
<s2>Toulouse</s2>
<s3>FRA</s3>
<sZ>7 aut.</sZ>
</fA14>
<fA14 i1="08"><s1>The National Hospital for Neurology and Neurosurgery</s1>
<s2>London</s2>
<s3>GBR</s3>
<sZ>8 aut.</sZ>
</fA14>
<fA15 i1="01"><s1>Institute of Neurology, and The National Hospital for Neurology and Neurosurgery</s1>
<s2>London</s2>
<s3>GBR</s3>
<sZ>1 aut.</sZ>
</fA15>
<fA17 i1="01" i2="1"><s1>PKDS009 Study Group</s1>
<s3>INC</s3>
</fA17>
<fA20><s1>23-30</s1>
</fA20>
<fA21><s1>1998</s1>
</fA21>
<fA23 i1="01"><s0>ENG</s0>
</fA23>
<fA43 i1="01"><s1>INIST</s1>
<s2>15326</s2>
<s5>354000078173570040</s5>
</fA43>
<fA44><s0>0000</s0>
<s1>© 1998 INIST-CNRS. All rights reserved.</s1>
</fA44>
<fA45><s0>21 ref.</s0>
</fA45>
<fA47 i1="01" i2="1"><s0>98-0176336</s0>
</fA47>
<fA60><s1>P</s1>
<s2>C</s2>
</fA60>
<fA61><s0>A</s0>
</fA61>
<fA64 i2="1"><s0>Drugs : (Basel)</s0>
</fA64>
<fA66 i1="01"><s0>NZL</s0>
</fA66>
<fC01 i1="01" l="ENG"><s0>This multicentre randomised double-blind 3- to 5-year trial was designed to assess whether initial therapy with cabergoline alone or in combination with levodopa prevents or delays the occurrence of long term motor complications in patients with early Parkinson's disease. Patients eligible for study inclusion (n = 412) had early idiopathic Parkinson's disease (Hoehn and Yahr stages 1 to 3) and had received no previous treatment with levodopa, selegiline or dopamine agonists. Patients were randomised to receive either cabergoline (0.25 to 4mg once daily) or levodopa (100 to 600 mg/day) titrated over a maximum period of 24 weeks. Once the optimum or maximum tolerated dose was achieved, it was maintained up to the end-point (development of motor complications confirmed at 2 consecutive 3-month visits) or up to a minimum of 3 years' treatment. Open labelled levodopa was added in both treatment arms when the improvement in motor disability [Unified Parkinson's Disease Rating Scale (UPDRS) factor III] decreased below 30% vs baseline. Both treatments improved motor disability, decreasing UPDRS factor III scores and factor II scores for activities of daily living. The development of motor complications (end-point) was significantly less frequent in patients treated with cabergoline than in levodopa recipients (22% vs 34% ; p < 0.02). The relative risk of developing motor complications during treatment with cabergoline was more than 50% lower than with levodopa. Serious adverse events, either drug related or not, were slightly more frequent in cabergoline-treated patients (31%) than in those treated with levodopa (25%). The withdrawal rate in the cabergoline v-I levodopa group was 16 vs 13%. In conclusion, the study shows that, in patients with early Parkinson's disease, cabergoline is effective either as monotherapy or combined with levodopa. Moreover, starting treatment with cabergoline significantly delays the development of motor complications.</s0>
</fC01>
<fC02 i1="01" i2="X"><s0>002B02B06</s0>
</fC02>
<fC03 i1="01" i2="X" l="FRE"><s0>Cabergoline</s0>
<s2>NK</s2>
<s2>FR</s2>
<s5>01</s5>
</fC03>
<fC03 i1="01" i2="X" l="ENG"><s0>Cabergoline</s0>
<s2>NK</s2>
<s2>FR</s2>
<s5>01</s5>
</fC03>
<fC03 i1="01" i2="X" l="SPA"><s0>Cabergolina</s0>
<s2>NK</s2>
<s2>FR</s2>
<s5>01</s5>
</fC03>
<fC03 i1="02" i2="X" l="FRE"><s0>Chimiothérapie</s0>
<s5>04</s5>
</fC03>
<fC03 i1="02" i2="X" l="ENG"><s0>Chemotherapy</s0>
<s5>04</s5>
</fC03>
<fC03 i1="02" i2="X" l="SPA"><s0>Quimioterapia</s0>
<s5>04</s5>
</fC03>
<fC03 i1="03" i2="X" l="FRE"><s0>Traitement</s0>
<s5>07</s5>
</fC03>
<fC03 i1="03" i2="X" l="ENG"><s0>Treatment</s0>
<s5>07</s5>
</fC03>
<fC03 i1="03" i2="X" l="GER"><s0>Aufbereiten</s0>
<s5>07</s5>
</fC03>
<fC03 i1="03" i2="X" l="SPA"><s0>Tratamiento</s0>
<s5>07</s5>
</fC03>
<fC03 i1="04" i2="X" l="FRE"><s0>Précoce</s0>
<s5>10</s5>
</fC03>
<fC03 i1="04" i2="X" l="ENG"><s0>Early</s0>
<s5>10</s5>
</fC03>
<fC03 i1="04" i2="X" l="SPA"><s0>Precoz</s0>
<s5>10</s5>
</fC03>
<fC03 i1="05" i2="X" l="FRE"><s0>Prévention</s0>
<s5>11</s5>
</fC03>
<fC03 i1="05" i2="X" l="ENG"><s0>Prevention</s0>
<s5>11</s5>
</fC03>
<fC03 i1="05" i2="X" l="SPA"><s0>Prevención</s0>
<s5>11</s5>
</fC03>
<fC03 i1="06" i2="X" l="FRE"><s0>Toxicité</s0>
<s5>12</s5>
</fC03>
<fC03 i1="06" i2="X" l="ENG"><s0>Toxicity</s0>
<s5>12</s5>
</fC03>
<fC03 i1="06" i2="X" l="GER"><s0>Giftigkeit</s0>
<s5>12</s5>
</fC03>
<fC03 i1="06" i2="X" l="SPA"><s0>Toxicidad</s0>
<s5>12</s5>
</fC03>
<fC03 i1="07" i2="X" l="FRE"><s0>Parkinson maladie</s0>
<s5>13</s5>
</fC03>
<fC03 i1="07" i2="X" l="ENG"><s0>Parkinson disease</s0>
<s5>13</s5>
</fC03>
<fC03 i1="07" i2="X" l="SPA"><s0>Parkinson enfermedad</s0>
<s5>13</s5>
</fC03>
<fC03 i1="08" i2="X" l="FRE"><s0>Homme</s0>
<s5>14</s5>
</fC03>
<fC03 i1="08" i2="X" l="ENG"><s0>Human</s0>
<s5>14</s5>
</fC03>
<fC03 i1="08" i2="X" l="SPA"><s0>Hombre</s0>
<s5>14</s5>
</fC03>
<fC03 i1="09" i2="X" l="FRE"><s0>Etude multicentrique</s0>
<s5>16</s5>
</fC03>
<fC03 i1="09" i2="X" l="ENG"><s0>Multicenter study</s0>
<s5>16</s5>
</fC03>
<fC03 i1="09" i2="X" l="SPA"><s0>Estudio multicéntrico</s0>
<s5>16</s5>
</fC03>
<fC03 i1="10" i2="X" l="FRE"><s0>Randomisation</s0>
<s5>17</s5>
</fC03>
<fC03 i1="10" i2="X" l="ENG"><s0>Randomization</s0>
<s5>17</s5>
</fC03>
<fC03 i1="10" i2="X" l="SPA"><s0>Aleatorización</s0>
<s5>17</s5>
</fC03>
<fC03 i1="11" i2="X" l="FRE"><s0>Etude double insu</s0>
<s5>18</s5>
</fC03>
<fC03 i1="11" i2="X" l="ENG"><s0>Double blind study</s0>
<s5>18</s5>
</fC03>
<fC03 i1="11" i2="X" l="SPA"><s0>Estudio doble ciego</s0>
<s5>18</s5>
</fC03>
<fC03 i1="12" i2="X" l="FRE"><s0>Essai thérapeutique contrôlé</s0>
<s5>19</s5>
</fC03>
<fC03 i1="12" i2="X" l="ENG"><s0>Controlled therapeutic trial</s0>
<s5>19</s5>
</fC03>
<fC03 i1="12" i2="X" l="SPA"><s0>Ensayo terapéutico controlado</s0>
<s5>19</s5>
</fC03>
<fC03 i1="13" i2="X" l="FRE"><s0>Ergot dérivé</s0>
<s5>25</s5>
</fC03>
<fC03 i1="13" i2="X" l="ENG"><s0>Ergot derivatives</s0>
<s5>25</s5>
</fC03>
<fC03 i1="13" i2="X" l="SPA"><s0>Ergot derivado</s0>
<s5>25</s5>
</fC03>
<fC07 i1="01" i2="X" l="FRE"><s0>Système nerveux pathologie</s0>
<s5>69</s5>
</fC07>
<fC07 i1="01" i2="X" l="ENG"><s0>Nervous system diseases</s0>
<s5>69</s5>
</fC07>
<fC07 i1="01" i2="X" l="SPA"><s0>Sistema nervioso patología</s0>
<s5>69</s5>
</fC07>
<fC07 i1="02" i2="X" l="FRE"><s0>Système nerveux central pathologie</s0>
<s5>70</s5>
</fC07>
<fC07 i1="02" i2="X" l="ENG"><s0>Central nervous system disease</s0>
<s5>70</s5>
</fC07>
<fC07 i1="02" i2="X" l="SPA"><s0>Sistema nervosio central patología</s0>
<s5>70</s5>
</fC07>
<fC07 i1="03" i2="X" l="FRE"><s0>Encéphale pathologie</s0>
<s5>71</s5>
</fC07>
<fC07 i1="03" i2="X" l="ENG"><s0>Cerebral disorder</s0>
<s5>71</s5>
</fC07>
<fC07 i1="03" i2="X" l="SPA"><s0>Encéfalo patología</s0>
<s5>71</s5>
</fC07>
<fC07 i1="04" i2="X" l="FRE"><s0>Extrapyramidal syndrome</s0>
<s5>72</s5>
</fC07>
<fC07 i1="04" i2="X" l="ENG"><s0>Extrapyramidal syndrome</s0>
<s5>72</s5>
</fC07>
<fC07 i1="04" i2="X" l="SPA"><s0>Extrapiramidal síndrome</s0>
<s5>72</s5>
</fC07>
<fC07 i1="05" i2="X" l="FRE"><s0>Maladie dégénérative</s0>
<s5>73</s5>
</fC07>
<fC07 i1="05" i2="X" l="ENG"><s0>Degenerative disease</s0>
<s5>73</s5>
</fC07>
<fC07 i1="05" i2="X" l="SPA"><s0>Enfermedad degenerativa</s0>
<s5>73</s5>
</fC07>
<fN21><s1>117</s1>
</fN21>
</pA>
<pR><fA30 i1="01" i2="1" l="ENG"><s1>Cabergoline: Advantages of Sustained Dopaminergic Stimulation. Satellite Symposium</s1>
<s3>London GBR</s3>
<s4>1997-03</s4>
</fA30>
</pR>
</standard>
<server><NO>PASCAL 98-0176336 INIST</NO>
<ET>Early treatment of Parkinson's Disease with cabergoline delays the onset of motor complications: Results of a double-blind levodopa controlled trial</ET>
<AU>RINNE (U. K.); BRACCO (F.); CHOUZA (C.); DUPONT (E.); GERSHANIK (O.); MARTI MASSO (J. F.); MONTASTRUC (J. L.); MARSDEN (C. D.); MARSDEN (C. D.)</AU>
<AF>Department of Neurology, University of Turku/Turku/Finlande (1 aut.); Clinica Neurologica, Università di Padova/Padova/Italie (2 aut.); Instituto de Neurologia, Hospital de Clinicas/Montevideo/Uruguay (3 aut.); Department of Neurology, Århus Kommunehospital/Århus/Danemark (4 aut.); Centro Neurologico, Hospital Frances/Buenos Aires/Argentine (5 aut.); Department of Neurology, Hospital Ntra. Sra. de Aranzazu/San Sebastian/Espagne (6 aut.); Centre Hospitalier Universitaire/Toulouse/France (7 aut.); The National Hospital for Neurology and Neurosurgery/London/Royaume-Uni (8 aut.); Institute of Neurology, and The National Hospital for Neurology and Neurosurgery/London/Royaume-Uni (1 aut.)</AF>
<DT>Publication en série; Congrès; Niveau analytique</DT>
<SO>Drugs : (Basel); ISSN 0012-6667; Coden DRUGAY; Nouvelle-Zélande; Da. 1998; Vol. 55; No. SUP1; Pp. 23-30; Bibl. 21 ref.</SO>
<LA>Anglais</LA>
<EA>This multicentre randomised double-blind 3- to 5-year trial was designed to assess whether initial therapy with cabergoline alone or in combination with levodopa prevents or delays the occurrence of long term motor complications in patients with early Parkinson's disease. Patients eligible for study inclusion (n = 412) had early idiopathic Parkinson's disease (Hoehn and Yahr stages 1 to 3) and had received no previous treatment with levodopa, selegiline or dopamine agonists. Patients were randomised to receive either cabergoline (0.25 to 4mg once daily) or levodopa (100 to 600 mg/day) titrated over a maximum period of 24 weeks. Once the optimum or maximum tolerated dose was achieved, it was maintained up to the end-point (development of motor complications confirmed at 2 consecutive 3-month visits) or up to a minimum of 3 years' treatment. Open labelled levodopa was added in both treatment arms when the improvement in motor disability [Unified Parkinson's Disease Rating Scale (UPDRS) factor III] decreased below 30% vs baseline. Both treatments improved motor disability, decreasing UPDRS factor III scores and factor II scores for activities of daily living. The development of motor complications (end-point) was significantly less frequent in patients treated with cabergoline than in levodopa recipients (22% vs 34% ; p < 0.02). The relative risk of developing motor complications during treatment with cabergoline was more than 50% lower than with levodopa. Serious adverse events, either drug related or not, were slightly more frequent in cabergoline-treated patients (31%) than in those treated with levodopa (25%). The withdrawal rate in the cabergoline v-I levodopa group was 16 vs 13%. In conclusion, the study shows that, in patients with early Parkinson's disease, cabergoline is effective either as monotherapy or combined with levodopa. Moreover, starting treatment with cabergoline significantly delays the development of motor complications.</EA>
<CC>002B02B06</CC>
<FD>Cabergoline; Chimiothérapie; Traitement; Précoce; Prévention; Toxicité; Parkinson maladie; Homme; Etude multicentrique; Randomisation; Etude double insu; Essai thérapeutique contrôlé; Ergot dérivé</FD>
<FG>Système nerveux pathologie; Système nerveux central pathologie; Encéphale pathologie; Extrapyramidal syndrome; Maladie dégénérative</FG>
<ED>Cabergoline; Chemotherapy; Treatment; Early; Prevention; Toxicity; Parkinson disease; Human; Multicenter study; Randomization; Double blind study; Controlled therapeutic trial; Ergot derivatives</ED>
<EG>Nervous system diseases; Central nervous system disease; Cerebral disorder; Extrapyramidal syndrome; Degenerative disease</EG>
<GD>Aufbereiten; Giftigkeit</GD>
<SD>Cabergolina; Quimioterapia; Tratamiento; Precoz; Prevención; Toxicidad; Parkinson enfermedad; Hombre; Estudio multicéntrico; Aleatorización; Estudio doble ciego; Ensayo terapéutico controlado; Ergot derivado</SD>
<LO>INIST-15326.354000078173570040</LO>
<ID>98-0176336</ID>
</server>
</inist>
</record>

Pour manipuler ce document sous Unix (Dilib)

EXPLOR_STEP=$WICRI_ROOT/Wicri/Sante/explor/ParkinsonFranceV1/Data/PascalFrancis/Corpus

HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 001632 | SxmlIndent | more

HfdSelect -h $EXPLOR_AREA/Data/PascalFrancis/Corpus/biblio.hfd -nk 001632 | SxmlIndent | more

Pour mettre un lien sur cette page dans le réseau Wicri

{{Explor lien
   |wiki=    Wicri/Sante
   |area=    ParkinsonFranceV1
   |flux=    PascalFrancis
   |étape=   Corpus
   |type=    RBID
   |clé=     Pascal:98-0176336
   |texte=   Early treatment of Parkinson's Disease with cabergoline delays the onset of motor complications: Results of a double-blind levodopa controlled trial
}}

This area was generated with Dilib version V0.6.29.
Data generation: Wed May 17 19:46:39 2017. Site generation: Mon Mar 4 15:48:15 2024

	La maladie de Parkinson en France (serveur d'exploration)
	Attention, ce site est en cours de développement ! Attention, site généré par des moyens informatiques à partir de corpus bruts. Les informations ne sont donc pas validées.

La maladie de Parkinson en France (serveur d'exploration)

Early treatment of Parkinson's Disease with cabergoline delays the onset of motor complications: Results of a double-blind levodopa controlled trial

Early treatment of Parkinson's Disease with cabergoline delays the onset of motor complications: Results of a double-blind levodopa controlled trial

Source :

Descripteurs français

English descriptors

Abstract

Notice en format standard (ISO 2709)

Format Inist (serveur)

Links to Exploration step

Le document en format XML

Pour manipuler ce document sous Unix (Dilib)

Pour mettre un lien sur cette page dans le réseau Wicri